NCT06309277Recruiting
A Clinical Study to Evaluate of Single and Multiple Oral Doses of GM-1020 in Patients With MDD
A Two-Part Controlled Clinical Study to Evaluate Safety, Tolerability, Response, Pharmacokinetics and Pharmacodynamics of Single and Multiple Oral Doses of GM-1020 in Patients With Major Depressive Disorder
Gilgamesh PharmaceuticalsPhase 2ClinicalTrials.govdrug
Study focus
- Disease/Condition
- Major Depressive Disorder
- Drug/Device/Intervention
- GM-1020
- Study type
- Interventional
- Intervention type
- drug
Sponsor & location
- Primary sponsor
- Gilgamesh Pharmaceuticals
- Location
- Manchester, United Kingdom
Timeline & enrollment
- Phase
- Phase 2
- Start date
- Feb 01, 2024
- End date
- Jul 01, 2024
- Enrollment
- 30 participants
Primary outcome
Incidence of treatment emergent adverse events
Summary
The aim of this Phase 2a study in patients with MDD is to assess safety and tolerability and
 preliminary antidepressant efficacy.
ICD-10 classifications
Recurrent depressive disorderRecurrent depressive disorder, unspecifiedDepressive conduct disorderOther recurrent depressive disordersRecurrent depressive disorder, current episode moderate
Data source
- Registry
- ClinicalTrials.gov
- Trial ID
- NCT06309277
- Type
- Non-Device Trial
About this record
Access comprehensive clinical trial information for NCT06309277 through Pure Global AI's free database. This Phase 2 trial is sponsored by Gilgamesh Pharmaceuticals and is currently Recruiting. The study focuses on Major Depressive Disorder. Target enrollment is 30 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.